{"created":"2023-05-15T14:36:03.490132+00:00","id":46409,"links":{},"metadata":{"_buckets":{"deposit":"517c3ae0-c925-4d56-83a9-c8915c0a2afb"},"_deposit":{"created_by":1,"id":"46409","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"46409"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00046409","sets":["1"]},"author_link":["462306","462302","462301","462305","462304","462300","462307","462303"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2011-06","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"6","bibliographicPageEnd":"2360","bibliographicPageStart":"2351","bibliographicVolumeNumber":"31","bibliographic_titles":[{"bibliographic_title":"Anticancer Research"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"AIM: We investigated whether hypoxia-inducible factor-1aphpa (HIF-1aphpa) expression in pretreatment biopsies of esophageal cancer is predictive of clinical outcome in patients with esophageal cancer undergoing concurrent chemoradiotherapy (CRT). PATIENTS AND METHODS: A total of 25 patients were reviewed. Radiotherapy was administered to total doses of 40-66.6 Gy (median: 66.6 Gy) with a single fraction of 1.8-2 Gy. Cisplatin (80 mg/m2 on day 1) and 5-fluorouracil (800 mg/m2 on days 2-6) were administered concurrently with radiotherapy, every 3-4 weeks to a total of 1-2 courses. Tissue samples from esophageal cancer were obtained from all 25 patients by biopsy before concurrent CRT, and semiquantitative analyses of HIF-1aphpa expression were performed using immunohistochemical staining. RESULTS:High HIF-1aphpa expression was observed in 11 out of 25 patients (42.7%), and HIF-1aphpa expression was significantly correlated with initial response to CRT (p=0.0027). Patients with high HIF-1aphpa expression had significantly poorer local control (LC) (5-year LC: 42.7%) than those with low expression (5-year LC: 72.5%; p=0.0322). Patients with high HIF-1aphpa expression also had significantly lower recurrence-free survival (RFS) (5-year RFS: 18.2%) compared to those with low HIF-1aphpa expression (5-year RFS: 39.8%; p=0.0009), and on multivariate analysis, HIF-1aphpa (p=0.001) and number of chemotherapy courses (p=0.010) were independent prognostic factors for RFS. CONCLUSION: HIF-1aphpa expression is significantly correlated with initial response to concurrent CRT, and is predictive of RFS for patients with esophageal cancer receiving concurrent CRT.","subitem_description_type":"Abstract"}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0250-7005","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Ogawa, Kazuhiko"}],"nameIdentifiers":[{"nameIdentifier":"462300","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Chiba, Itaru"}],"nameIdentifiers":[{"nameIdentifier":"462301","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Morioka, Takamitsu"}],"nameIdentifiers":[{"nameIdentifier":"462302","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yoshimi, Naoki"}],"nameIdentifiers":[{"nameIdentifier":"462303","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Murayama, Sadayuki"}],"nameIdentifiers":[{"nameIdentifier":"462304","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"et.al"}],"nameIdentifiers":[{"nameIdentifier":"462305","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"森岡 孝満","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"462306","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"吉見 直己","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"462307","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Clinical significance of HIF-1alpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Clinical significance of HIF-1alpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy."}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2012-10-02"},"publish_date":"2012-10-02","publish_status":"0","recid":"46409","relation_version_is_last":true,"title":["Clinical significance of HIF-1alpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy."],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T23:52:10.039989+00:00"}